Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter

K. Cerna, D. Duricova, M. Lukas, M. Kolar, N. Machkova, V. Hruba, K. Mitrova, K. Kubickova, M. Kostrejova, J. Jirsa, K. Kastylova, S. Peterka, G. Vojtechova, M. Lukas

. 2023 ; 5 (4) : otad040. [pub] 20230725

Status neindexováno Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23022785

BACKGROUND: A subcutaneous formulation of infliximab (IFX-SC) approved to treat patients with inflammatory bowel disease may offer improved efficacy versus intravenous infliximab. METHODS: Patients with refractory Crohn's disease (CD, n = 32) previously treated unsuccessfully with at least 2 biologics were treated with IFX-SC and followed from baseline at Week 0 (W0) to Week 30 (W30). The study's primary endpoint was the treatment's persistence at W30, while secondary goals included the analysis of serum infliximab trough levels (TL IFX), dynamics of anti-IFX antibodies (ATIs), and clinical, serum and fecal markers of CD activity during IFX-SC treatment. RESULTS: Midterm treatment persistence with the continuation of treatment after W30 was 53%. TL IFX median values showed rapid, significant upward dynamics and exceeded 15.5 μg/mL at W30, whereas median ATI levels significantly declined. Among ATI-negative patients at W0 (n = 15), only one showed IFX immunogenicity with newly developed ATIs at W30. Among ATI-positive patients at W0, ATI seroconversion from ATI-positive to ATI-negative status was observed in 10 of 17 patients (58.8%). Patients who had continued IFX-SC treatment at W30 showed significant decreases in C-reactive protein (P = .0341), fecal calprotectin (P = .0002), and Harvey-Bradshaw index (P = .0029) since W0. CONCLUSIONS: Patients with refractory CD previously treated with at least 2 biologics exhibited clinically relevant improvement with IFX-SC, which showed less immunogenic potential than IFX-IV and highly stable TL IFX.

000      
00000naa a2200000 a 4500
001      
bmc23022785
003      
CZ-PrNML
005      
20240116163132.0
007      
ta
008      
240105s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/crocol/otad040 $2 doi
035    __
$a (PubMed)38028954
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Cerna, Karin $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u GENNET, Prague, Czech Republic $1 https://orcid.org/0000000315935899 $7 xx0096040
245    10
$a Subcutaneous Infliximab in Refractory Crohn's Disease Patients: A Possible Biobetter / $c K. Cerna, D. Duricova, M. Lukas, M. Kolar, N. Machkova, V. Hruba, K. Mitrova, K. Kubickova, M. Kostrejova, J. Jirsa, K. Kastylova, S. Peterka, G. Vojtechova, M. Lukas
520    9_
$a BACKGROUND: A subcutaneous formulation of infliximab (IFX-SC) approved to treat patients with inflammatory bowel disease may offer improved efficacy versus intravenous infliximab. METHODS: Patients with refractory Crohn's disease (CD, n = 32) previously treated unsuccessfully with at least 2 biologics were treated with IFX-SC and followed from baseline at Week 0 (W0) to Week 30 (W30). The study's primary endpoint was the treatment's persistence at W30, while secondary goals included the analysis of serum infliximab trough levels (TL IFX), dynamics of anti-IFX antibodies (ATIs), and clinical, serum and fecal markers of CD activity during IFX-SC treatment. RESULTS: Midterm treatment persistence with the continuation of treatment after W30 was 53%. TL IFX median values showed rapid, significant upward dynamics and exceeded 15.5 μg/mL at W30, whereas median ATI levels significantly declined. Among ATI-negative patients at W0 (n = 15), only one showed IFX immunogenicity with newly developed ATIs at W30. Among ATI-positive patients at W0, ATI seroconversion from ATI-positive to ATI-negative status was observed in 10 of 17 patients (58.8%). Patients who had continued IFX-SC treatment at W30 showed significant decreases in C-reactive protein (P = .0341), fecal calprotectin (P = .0002), and Harvey-Bradshaw index (P = .0029) since W0. CONCLUSIONS: Patients with refractory CD previously treated with at least 2 biologics exhibited clinically relevant improvement with IFX-SC, which showed less immunogenic potential than IFX-IV and highly stable TL IFX.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Duricova, Dana $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Pharmacology, First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000260903522 $7 xx0118363
700    1_
$a Lukas, Martin $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic $u Department of Surgery, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000303565480
700    1_
$a Kolar, Martin $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Libechov, Czech Republic
700    1_
$a Machkova, Nadezda $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hruba, Veronika $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Mitrova, Katarina $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000218363745
700    1_
$a Kubickova, Kristyna $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000312579171
700    1_
$a Kostrejova, Marta $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Internal Medicine, Hospital of the Sisters of Mercy of St. Charles Borromeo, Prague, Czech Republic
700    1_
$a Jirsa, Jakub $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kastylova, Kristyna $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Peterka, Stepan $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Internal Medicine, Hospital Jindrichuv Hradec, Jindrichuv Hradec, Czech Republic
700    1_
$a Vojtechova, Gabriela $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $u ResTrial GastroEndo, Prague, Czech Republic $1 https://orcid.org/000000027911470X $7 xx0229119
700    1_
$a Lukas, Milan $u Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000214633840 $7 jn19990202012
773    0_
$w MED00213971 $t Crohn's & colitis 360 $x 2631-827X $g Roč. 5, č. 4 (2023), s. otad040
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38028954 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240105 $b ABA008
991    __
$a 20240116163129 $b ABA008
999    __
$a ok $b bmc $g 2036392 $s 1209230
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 5 $c 4 $d otad040 $e 20230725 $i 2631-827X $m Crohn's & colitis 360 $n Crohns Colitis 360 $x MED00213971
LZP    __
$a Pubmed-20240105

Najít záznam

Citační ukazatele

Možnosti archivace